Pseudogene-Derived lncRNAs and Their miRNA Sponging Mechanism in Human Cancer

Lou, Weiyang; Ding, Bo; Fu, Peifen

doi:10.3389/fcell.2020.00085

Cited by 120 publications

(108 citation statements)

References 140 publications

Supporting

Mentioning

107

Contrasting

Order By: Relevance

“…CeRNA is an important concept in which lncRNAs interact with miRNA thus to de-repress the mRNA targets of miRNAs [13][14][15]. There are numerous reports characterizing the modulation of lncRNAs as ceRNAs in CC [23][24][25].…”

Section: Discussionmentioning

confidence: 99%

HOXD-AS1 facilitates cell migration and invasion as an oncogenic lncRNA by competitively binding to miR-877-3p and upregulating FGF2 in human cervical cancer

Chen

2020

BMC Cancer

View full text Add to dashboard Cite

Background Long non-coding RNAs (LncRNAs) are dysregulated in multiple human cancers and they are highly involved in tumor progression. Previous studies have identified the oncogenic lncRNA HOXD cluster antisense RNA 1 (HOXD-AS1) in human cancers, while its roles in cervical cancer (CC) remain unclear. Herein we intended to characterize the implication of HOXD-AS1 in CC. Methods qRT-PCR was applied to examine the relative expression of HOXD-AS1 in CC tissues, cell lines and transfected cells. Wound healing and transwell assays were applied to detect cell migration and invasion alteration. The targeting relationship between miRNA and mRNA/lncRNA was determined by dual luciferase reporter, qRT-PCR and western blot assays. Results HOXD-AS1 was overexpressed in CC tissues and cell lines. Its higher level predicted worse prognosis of CC patients. SiRNA mediated knockdown of HOXD-AS1 repressed CC cell migration and invasion, and its overexpression did the opposite. Mechanistically, HOXD-AS1 acted as a competing endogenous RNA (ceRNA) to sponge miR-877-3p and led to upregulation of FGF2, a target of miR-877-3p. Importantly, either miR-877-3p overexpression or FGF2 inhibition could abolish the migration and invasion promotion induced by HOXD-AS1. Conclusion HOXD-AS1 functions as a tumor-promoting lncRNA via the miR-877-3p/FGF2 axis in CC. HOXD-AS1 might be a promising therapeutic target as well as a novel prognostic biomarker for CC.

show abstract

Section: Discussionmentioning

confidence: 99%

HOXD-AS1 facilitates cell migration and invasion as an oncogenic lncRNA by competitively binding to miR-877-3p and upregulating FGF2 in human cervical cancer

Chen

2020

BMC Cancer

View full text Add to dashboard Cite

show abstract

“…LncRNAs are recently emerging as key factors of tumorigenesis [32]. LncRNA regulates gene expression at three levels: apparent modification, transcription, and post-transcriptional translation [33]. It is thought to play an important role in the development of many tumors.…”

Section: Discussionmentioning

confidence: 99%

Prognostic and clinicopathological significance of long noncoding RNA MALAT-1 expression in patients with non-small cell lung cancer: A meta-analysis

et al. 2020

View full text Add to dashboard Cite

Background Although expression of long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT-1) in tumor tissues has been assessed in several malignancies. However, the association between lncRNA MALAT-1 expression and prognosis or clinicopathological feature remains controversial. Therefore, we conducted a meta-analysis to verify whether lncRNA MALAT-1 expression was associated with prognosis or clinicopathological features in patients with non-small cell lung cancer (NSCLC). Methods We searched Embase, PubMed, Web of Science, Cochrane library, The Chinese National Knowledge Infrastructure, and Wanfang databases from inception to March, 1, 2020. The language restrictions were Chinese and English. The published literature on lncRNA MALAT-l expression and prognosis or clinicopathological characteristics of NSCLC patients was statistically analyzed. Combined hazard ratios (HRs), odds ratios (OR), and 95% confidence intervals (95% CIs) were used to evaluate the effects of lncRNA MALAT-l on the prognosis and clinicopathological features of NSCLC. Results Fifteen studies with 1477 NSCLC patients were enrolled. The results showed that the elevated expression of lncRNA MALAT-l in tumor tissues was associated with shorter overall survival (OS) (

show abstract

“…Lncrna is a type of ncRNA with over 200 nucleotides, which has nothing to do with protein-coding [12][13][14][15][16]. New evidence suggests that lncRNA imbalance occurs frequently in many malignant tumours and are vital for carcinogenesis through post-transcriptional regulation and epigenetic modi cation [17,18]. Here, we bioinformatically analysed the ceRNA network regulating bone metastasis of breast cancer with 20 protein encoded mRNAs, 2 lncRNAs and 18 miRNAs.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, an increasing number of studies show that aberrant lncrnas expression leads to the development of many kinds of malignant tumours, including breast cancer [12][13][14][15][16][17][18]. As a kind of lncrnas, dlx6-as1 is believed to be carcinogenic by regulating the progression of renal cell carcinoma, liver cell carcinoma, glioma, pancreatic cancer and lung adenocarcinoma [19][20][21][22][23][24][25][26].…”

Section: Discussionmentioning

confidence: 99%

ceRNA Network Development and Tumour-infiltrating Immune Cell Analysis in Metastatic Breast Cancer of Bone

Liu

Song

Zhou

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Advanced breast cancer commonly metastasises to the bone and the molecular mechanism explaining the bone affinity of breast cancer cells is unclear. Thus, we developed nomograms based on a competing endogenous RNA (ceRNA) network and analysed tumour-infiltrating immunecells to elucidate the molecular pathways that may predict the prognosis of breast cancer patients.Methods: We obtained the RNA expression profile of 1091 primary breast cancer samples from The Cancer Genome Atlas database, 58 of which had bone metastasis. We analysed differential RNA expression patterns between breast cancer with and without bone metastasis and developed a ceRNA network. Cibersort was employed to differentiate between immune cell types based on tumour transcripts. Nomograms were then established using the ceRNA network and immune cell analysis. The value of prognostic factors was evaluated by Kaplan-Meier survival analysis and Cox proportional risk model.Results: There were significant differences in lncRNAs, 18 miRNAs, and 20mRNAs between breast cancer with and without bone metastasis, which were used to construct a ceRNA network. We found that the protein-coding genes gjb3, cammv, ptprz1,and fbn3 were significant in our Kaplan-Meier analysis. We also observed significant differences in plasma cell and follicular helper T cell populations between the two groups. In addition, the proportions of mast cells, gamma delta T cells, and plasma cells differed depending on disease location and stage. Our analysis revealed that a high proportion of follicular helper T cells and a low proportion of eosinophils promoted survival and that dlx6-as1, wnt6,and gabbr2expression may be related to bone metastasis of breast cancer.Conclusions: We provided a bioinformatic basis for exploring the molecular mechanism of bone metastasis in breast cancer patients and identified factors that may predict this.

show abstract

Pseudogene-Derived lncRNAs and Their miRNA Sponging Mechanism in Human Cancer

Cited by 120 publications

References 140 publications

HOXD-AS1 facilitates cell migration and invasion as an oncogenic lncRNA by competitively binding to miR-877-3p and upregulating FGF2 in human cervical cancer

HOXD-AS1 facilitates cell migration and invasion as an oncogenic lncRNA by competitively binding to miR-877-3p and upregulating FGF2 in human cervical cancer

Prognostic and clinicopathological significance of long noncoding RNA MALAT-1 expression in patients with non-small cell lung cancer: A meta-analysis

ceRNA Network Development and Tumour-infiltrating Immune Cell Analysis in Metastatic Breast Cancer of Bone

Contact Info

Product

Resources

About